ESR1 and neoplasm: Indeed, transcript profiling of gene panels selected to represent the variance across tumor subtypes is recommended for assigning treatment courses for patients with early stage ER+ /HER2− tumors2,3 and may prevent patients from receiving chemotherapy who do not stand to benefit38.